BIOGEN INC (BIIB)       288.265  +4.63 (+1.63%)

288.265  +4.63 (+1.63%)

US09062X1037 - Common Stock

BIOGEN INC288.265

NASDAQ:BIIB (2/6/2023, 10:28:04 AM)+4.63 (+1.63%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 02-01 2023-02-01/amc Earnings (Next) 05-01 2023-05-01/amc
Ins Owners 0.2% Inst Owners 84.8%
Market Cap 41.51B Shares 144.00M
PE 16.2 Fwd PE 18.04
Dividend Yield N/A Analysts 77.5
IPO 09-17 1991-09-17

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BIIB Daily chart

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 9,610 full-time employees. The company is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.

Company Info

BIOGEN INC

225 Binney Street

Cambridge MASSACHUSETTS 02142

P: 17814642000.0

CEO: Michel Vounatsos

Employees: 9610

Website: https://www.biogen.com/

BIIB News

News Image4 hours ago - Seeking AlphaBiogen, Sage win FDA priority review for depression therapy (NASDAQ:BIIB)

Biogen (BIIB) and Sage Therapeutics (SAGE) said Monday that FDA accepted the marketing application for oral depression therapy zuranolone under priority review. Read the full story here.

News Image5 hours ago - BloombergEisai Says US Launch of Alzheimer’s Drug ‘Ahead of Expectations’

Eisai Co.’s sales of the Alzheimer’s drug Leqembi in the US are “ahead of expectations” despite the steps required to administer it, said Ivan Cheung, the company’s global Alzheimer’s disease officer.

News Image5 hours ago - Biogen Inc.Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum DepressionNews Image5 hours ago - Sage Therapeutics, Inc.Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum DepressionNews Image5 hours ago - Biogen Inc.Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum...

News Image4 days ago - Investor's Business DailyHere's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

The company that remains still has a large pipeline of non-migraine assets.

BIIB Twits

Here you can normally see the latest stock twits on BIIB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example